These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28865972)

  • 1. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.
    Lee SY; Meehan RS; Seldin DC; Sloan JM; Quillen K; Shelton A; Brauneis D; Sanchorawala V
    Bone Marrow Transplant; 2016 Oct; 51(10):1318-1322. PubMed ID: 27183092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
    Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.
    Nader R; Zhen A; Angel-Korman A; Pavlovich SS; Pogrebinsky A; Doros G; Menn-Josephy H; Stern L; Sanchorawala V; Havasi A
    Nephrol Dial Transplant; 2022 Jun; 37(7):1281-1288. PubMed ID: 34043009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
    Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
    Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
    Quillen K; Seldin DC; Finn KT; Sanchorawala V
    Bone Marrow Transplant; 2011 Jul; 46(7):976-80. PubMed ID: 20956955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
    Gustine JN; Staron A; Szalat RE; Mendelson LM; Joshi T; Ruberg FL; Siddiqi O; Gopal DM; Edwards CV; Havasi A; Kaku M; Lau KHV; Berk JL; Sloan JM; Sanchorawala V
    Am J Hematol; 2022 Sep; 97(9):1189-1199. PubMed ID: 35731907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
    Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
    BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.